|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.350 USD | 0.00% |
|
+4.65% | -61.76% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
Company Valuation: ADC Therapeutics SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,550 | 306.9 | 134.1 | 192.4 | 437.3 | 171.7 | - | - |
| Change | - | -80.2% | -56.31% | 43.49% | 127.27% | -60.73% | - | - |
| Enterprise Value (EV) | 1,092 | 90.22 | -20.12 | 192.4 | 437.3 | 171.7 | 171.7 | 171.7 |
| Change | - | -91.74% | -122.31% | 1,056.12% | 127.27% | -60.73% | 0% | 0% |
| P/E | -6.73x | -1.93x | -0.56x | -1.23x | -3.15x | -1.58x | -2.04x | -24.5x |
| PBR | 9.34x | 3.49x | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | 0x | 0.1x | 0.1x | 0.1x | 0.3x |
| Capitalization / Revenue | 45.7x | 1.46x | 1.93x | 2.72x | 5.37x | 2.12x | 1.39x | 0.67x |
| EV / Revenue | 0x | 0x | -0x | 0x | 0x | 2.12x | 1.39x | 0.67x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | -0x | -1.81x | -2.65x | 3.72x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3 | -1.99 | -2.94 | -1.62 | -1.12 | -0.856 | -0.6625 | -0.055 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 33.92 | 209.9 | 69.56 | 70.84 | 81.36 | 80.89 | 123.8 | 254.4 |
| EBITDA | -198.6 | -71.98 | - | - | - | - | - | - |
| EBIT 1 | -261.7 | -123.6 | -166 | -130.7 | -121.5 | -94.97 | -64.85 | 46.14 |
| Net income 1 | -230 | -155.8 | -240.1 | -157.8 | -142.6 | -136.1 | -117.3 | -7.638 |
| Net Debt | -458.5 | -216.7 | -154.2 | - | - | - | - | - |
| Reference price 2 | 20.200 | 3.840 | 1.660 | 1.990 | 3.530 | 1.350 | 1.350 | 1.350 |
| Nbr of stocks (in thousands) | 76,754 | 79,934 | 80,781 | 96,690 | 123,877 | 127,191 | - | - |
| Announcement Date | 3/3/22 | 2/28/23 | 3/13/24 | 3/27/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.58x | - | - | - | 172M | |
| 32.22x | 8.13x | 25.24x | 0.05% | 53.83B | |
| 19.5x | 6.01x | 13.15x | 1.63% | 52.1B | |
| -42.48x | 13.5x | -39.59x | -.--% | 23.48B | |
| -18.22x | 4.32x | -7.57x | -.--% | 23.13B | |
| 24.24x | 4.75x | 12.54x | -.--% | 19.36B | |
| 24.39x | 4.78x | 15.56x | -.--% | 17.56B | |
| 45.88x | 18.59x | 47.88x | 0.08% | 15.2B | |
| -505.73x | 35.47x | -1462.84x | -.--% | 14.83B | |
| 17.57x | 5.11x | 11.88x | -.--% | 14.06B | |
| Average | -40.42x | 11.19x | -153.75x | 0.2% | 23.37B | |
| Weighted average by Cap. | -18.51x | 9.52x | -82.82x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ADCT Stock
- Valuation ADC Therapeutics SA
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
